Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franz-Josef Neumann

Showing results (421-430 of 477) with videos related to

Pageof 48
Sort By:
Circulation. Cardiovascular Interventions|February 15, 2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)Jennifer Yu, Roxana Mehran, Usman Baber, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 2, 2021
Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. A multicenter observational study of the RETAC (reseau européen de traîtement d'arrhythmies cardiaques)-groupBjörn Müller-Edenborn, Zoraida Moreno-Weidmann, Sandrine Venier, et al.
JACC. Cardiovascular Interventions|September 22, 2022
Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial SubstudyGilles Montalescot, Alban Redheuil, Flavien Vincent, et al.
The American Journal of Cardiology|April 13, 2016
Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents StudyGennaro Giustino, Ajay J Kirtane, Philippe Généreux, et al.
Journal of the American College of Cardiology|November 20, 2020
Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary SyndromesChristian Valina, Franz-Josef Neumann, Maurizio Menichelli, et al.
European Heart Journal|May 18, 2022
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trialJean Philippe Collet, Eric Van Belle, Holger Thiele, et al.
Lancet (London, England)|September 1, 2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
American Heart Journal|March 22, 2019
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) studyMatthew T Finn, Björn Redfors, Dimitri Karmpaliotis, et al.
International Journal of Cardiology|January 2, 2017
Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stentsPhilippe Généreux, Björn Redfors, Bernhard Witzenbichler, et al.
Journal of the American Heart Association|December 24, 2022
On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DESBahira Shahim, Björn Redfors, Thomas D Stuckey, et al.
Pageof 48

Showing results (421-430 of 477) with videos related to

Sort By:
Pageof 48
Circulation. Cardiovascular Interventions|February 15, 2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)Jennifer Yu, Roxana Mehran, Usman Baber, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 2, 2021
Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. A multicenter observational study of the RETAC (reseau européen de traîtement d'arrhythmies cardiaques)-groupBjörn Müller-Edenborn, Zoraida Moreno-Weidmann, Sandrine Venier, et al.
JACC. Cardiovascular Interventions|September 22, 2022
Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial SubstudyGilles Montalescot, Alban Redheuil, Flavien Vincent, et al.
The American Journal of Cardiology|April 13, 2016
Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents StudyGennaro Giustino, Ajay J Kirtane, Philippe Généreux, et al.
Journal of the American College of Cardiology|November 20, 2020
Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary SyndromesChristian Valina, Franz-Josef Neumann, Maurizio Menichelli, et al.
European Heart Journal|May 18, 2022
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trialJean Philippe Collet, Eric Van Belle, Holger Thiele, et al.
Lancet (London, England)|September 1, 2017
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trialDirk Sibbing, Dániel Aradi, Claudius Jacobshagen, et al.
American Heart Journal|March 22, 2019
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) studyMatthew T Finn, Björn Redfors, Dimitri Karmpaliotis, et al.
International Journal of Cardiology|January 2, 2017
Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stentsPhilippe Généreux, Björn Redfors, Bernhard Witzenbichler, et al.
Journal of the American Heart Association|December 24, 2022
On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DESBahira Shahim, Björn Redfors, Thomas D Stuckey, et al.
Pageof 48